S&P 500   3,319.47 (-1.12%)
DOW   27,657.42 (-0.88%)
QQQ   266.87 (-1.28%)
AAPL   106.84 (-3.17%)
MSFT   200.39 (-1.24%)
FB   252.53 (-0.90%)
GOOGL   1,451.09 (-2.42%)
AMZN   2,954.91 (-1.79%)
NVDA   487.57 (-2.20%)
TSLA   442.15 (+4.42%)
BABA   272.41 (-1.20%)
CGC   16.36 (-0.24%)
GE   6.88 (-2.41%)
MU   50.74 (-0.47%)
AMD   74.93 (-2.12%)
T   28.93 (-0.48%)
F   7.23 (-0.69%)
ACB   6.53 (-5.22%)
GILD   65.05 (+0.02%)
NFLX   469.96 (-0.05%)
DIS   128.63 (-1.22%)
BAC   25.21 (-0.55%)
BA   161.14 (-3.81%)
S&P 500   3,319.47 (-1.12%)
DOW   27,657.42 (-0.88%)
QQQ   266.87 (-1.28%)
AAPL   106.84 (-3.17%)
MSFT   200.39 (-1.24%)
FB   252.53 (-0.90%)
GOOGL   1,451.09 (-2.42%)
AMZN   2,954.91 (-1.79%)
NVDA   487.57 (-2.20%)
TSLA   442.15 (+4.42%)
BABA   272.41 (-1.20%)
CGC   16.36 (-0.24%)
GE   6.88 (-2.41%)
MU   50.74 (-0.47%)
AMD   74.93 (-2.12%)
T   28.93 (-0.48%)
F   7.23 (-0.69%)
ACB   6.53 (-5.22%)
GILD   65.05 (+0.02%)
NFLX   469.96 (-0.05%)
DIS   128.63 (-1.22%)
BAC   25.21 (-0.55%)
BA   161.14 (-3.81%)
S&P 500   3,319.47 (-1.12%)
DOW   27,657.42 (-0.88%)
QQQ   266.87 (-1.28%)
AAPL   106.84 (-3.17%)
MSFT   200.39 (-1.24%)
FB   252.53 (-0.90%)
GOOGL   1,451.09 (-2.42%)
AMZN   2,954.91 (-1.79%)
NVDA   487.57 (-2.20%)
TSLA   442.15 (+4.42%)
BABA   272.41 (-1.20%)
CGC   16.36 (-0.24%)
GE   6.88 (-2.41%)
MU   50.74 (-0.47%)
AMD   74.93 (-2.12%)
T   28.93 (-0.48%)
F   7.23 (-0.69%)
ACB   6.53 (-5.22%)
GILD   65.05 (+0.02%)
NFLX   469.96 (-0.05%)
DIS   128.63 (-1.22%)
BAC   25.21 (-0.55%)
BA   161.14 (-3.81%)
S&P 500   3,319.47 (-1.12%)
DOW   27,657.42 (-0.88%)
QQQ   266.87 (-1.28%)
AAPL   106.84 (-3.17%)
MSFT   200.39 (-1.24%)
FB   252.53 (-0.90%)
GOOGL   1,451.09 (-2.42%)
AMZN   2,954.91 (-1.79%)
NVDA   487.57 (-2.20%)
TSLA   442.15 (+4.42%)
BABA   272.41 (-1.20%)
CGC   16.36 (-0.24%)
GE   6.88 (-2.41%)
MU   50.74 (-0.47%)
AMD   74.93 (-2.12%)
T   28.93 (-0.48%)
F   7.23 (-0.69%)
ACB   6.53 (-5.22%)
GILD   65.05 (+0.02%)
NFLX   469.96 (-0.05%)
DIS   128.63 (-1.22%)
BAC   25.21 (-0.55%)
BA   161.14 (-3.81%)
Log in
NASDAQ:NYMX

Nymox Pharmaceutical Stock Forecast, Price & News

$2.43
+0.06 (+2.53 %)
(As of 09/18/2020 12:00 AM ET)
Add
Compare
Today's Range
$2.34
Now: $2.43
$2.46
50-Day Range
$2.37
MA: $2.77
$3.30
52-Week Range
$1.66
Now: $2.43
$4.79
Volume188,161 shs
Average Volume215,513 shs
Market Capitalization$176.71 million
P/E RatioN/A
Dividend YieldN/A
Beta1.31
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease. Its lead drug candidate is Fexapotide Triflutate (NX-1207) that has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia; and is in Phase II clinical trial for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company markets its products in Canada, the United States, Europe, and internationally. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, Bahamas.
Read More
Nymox Pharmaceutical logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.70 out of 5 stars


Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NYMX
CUSIPN/A
Phone800-936-9669

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$120,000.00
Book Value$0.05 per share

Profitability

Net Income$-13,160,000.00
Net Margins-14,341.11%

Miscellaneous

EmployeesN/A
Market Cap$176.71 million
Next Earnings Date11/11/2020 (Estimated)
OptionableOptionable
$2.43
+0.06 (+2.53 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NYMX News and Ratings via Email

Sign-up to receive the latest news and ratings for NYMX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Nymox Pharmaceutical (NASDAQ:NYMX) Frequently Asked Questions

How has Nymox Pharmaceutical's stock been impacted by Coronavirus (COVID-19)?

Nymox Pharmaceutical's stock was trading at $2.29 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, NYMX stock has increased by 6.1% and is now trading at $2.43.
View which stocks have been most impacted by COVID-19
.

When is Nymox Pharmaceutical's next earnings date?

Nymox Pharmaceutical is scheduled to release its next quarterly earnings announcement on Wednesday, November 11th 2020.
View our earnings forecast for Nymox Pharmaceutical
.

How were Nymox Pharmaceutical's earnings last quarter?

Nymox Pharmaceutical Corp (NASDAQ:NYMX) issued its earnings results on Friday, November, 14th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter. The biopharmaceutical company had revenue of $0.08 million for the quarter. Nymox Pharmaceutical had a negative net margin of 14,341.11% and a negative return on equity of 451.84%.
View Nymox Pharmaceutical's earnings history
.

Are investors shorting Nymox Pharmaceutical?

Nymox Pharmaceutical saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 3,550,000 shares, an increase of 12.0% from the August 15th total of 3,170,000 shares. Based on an average trading volume of 264,100 shares, the days-to-cover ratio is currently 13.4 days. Currently, 8.1% of the company's stock are short sold.
View Nymox Pharmaceutical's Short Interest
.

Who are some of Nymox Pharmaceutical's key competitors?

What other stocks do shareholders of Nymox Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nymox Pharmaceutical investors own include Quantum (QTM), Rocket Pharmaceuticals (RCKT), Biocept (BIOC), TherapeuticsMD (TXMD), Catalyst Pharmaceuticals (CPRX), MEI Pharma (MEIP), Rigel Pharmaceuticals (RIGL), Synergy Pharmaceuticals (SGYP), CTI BioPharma (CTIC) and Idera Pharmaceuticals (IDRA).

Who are Nymox Pharmaceutical's key executives?

Nymox Pharmaceutical's management team includes the following people:
  • Dr. Paul Averback, Founder, Chairman, CEO & Pres (Age 68)
  • Mr. Erik Danielsen, Chief Financial Officer (Age 56)
  • Mr. Randall J. Lanham, Gen. Counsel, Sec. & Director (Age 55)

What is Nymox Pharmaceutical's stock symbol?

Nymox Pharmaceutical trades on the NASDAQ under the ticker symbol "NYMX."

Who are Nymox Pharmaceutical's major shareholders?

Nymox Pharmaceutical's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Nuveen Asset Management LLC (0.21%), Bank of New York Mellon Corp (0.13%), Strs Ohio (0.12%), California Public Employees Retirement System (0.12%), Charles Schwab Investment Management Inc. (0.12%) and Jane Street Group LLC (0.12%). Company insiders that own Nymox Pharmaceutical stock include Erik Danielsen, James George Robinson, Paul Averback and Randall J Lanham.
View institutional ownership trends for Nymox Pharmaceutical
.

Which institutional investors are selling Nymox Pharmaceutical stock?

NYMX stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., and Patriot Financial Group Insurance Agency LLC.
View insider buying and selling activity for Nymox Pharmaceutical
.

Which institutional investors are buying Nymox Pharmaceutical stock?

NYMX stock was bought by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Bank of New York Mellon Corp, Strs Ohio, Charles Schwab Investment Management Inc., California Public Employees Retirement System, Jane Street Group LLC, New York State Common Retirement Fund, and Virtu Financial LLC. Company insiders that have bought Nymox Pharmaceutical stock in the last two years include Erik Danielsen, James George Robinson, and Randall J Lanham.
View insider buying and selling activity for Nymox Pharmaceutical
.

How do I buy shares of Nymox Pharmaceutical?

Shares of NYMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Nymox Pharmaceutical's stock price today?

One share of NYMX stock can currently be purchased for approximately $2.43.

How big of a company is Nymox Pharmaceutical?

Nymox Pharmaceutical has a market capitalization of $176.71 million and generates $120,000.00 in revenue each year.

What is Nymox Pharmaceutical's official website?

The official website for Nymox Pharmaceutical is www.nymox.com.

How can I contact Nymox Pharmaceutical?

Nymox Pharmaceutical's mailing address is BAY & DEVEAUX STREETS, NASSAU C5, H4M 2V2. The biopharmaceutical company can be reached via phone at 800-936-9669 or via email at [email protected]

This page was last updated on 9/18/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.